


## Supplementary Appendix



### Supplementary Figure 1: Study Design

The study period with both policy interventions are displayed.

**Box 'A'** represents October 2011, the month prior to the enactment of the Narcotics Safety and Awareness Act (NSAA)

**Box 'B'** represents April 2012, the month prior to the implementation of the Narcotics Monitoring System (NMS)

**Box 'C'** represents May 2013, the end of the study period

To describe the impact of the NSAA, prevalence rates are compared between Boxes 'A' and 'B'.

To describe the impact of the NMS, prevalence rates are compared between Boxes 'B' and 'C'.

**Supplementary Table 1: Details of Time Series Analyses**

Drug Class	Model Specification	R-Squared	Enactment of NSAAs* (P-value)	Introduction of NMS** (P-value)
<b>Primary Analysis</b>				
Opioids	IAR (3,1,0)	0.98	0.01	0.78
Benzodiazepines	IAR (12, 1, 0)	0.93	<0.001	0.05
Stimulants	ARIMA (12,1,2)	0.80	0.06	0.02
NSAIDs	ARMA (4,0,1)	0.25	0.29	0.94
<b>Secondary Analysis</b>				
Opioids	ARIMA (6,1,1)	0.89	<0.001	<0.001
Benzodiazepines	ARIMA (2,1,1)	0.78	0.01	0.02
Stimulants	IAR (6,1,0)	0.73	0.04	0.13
<b>Sensitivity Analysis</b>				
Opioids	IAR (1,1,0)	0.98	0.03	0.44
Benzodiazepines	IAR (3,1,0)	0.93	<0.001	0.03
Stimulants	IAR (9,1,0)	0.81	0.02	0.22

\*NSAA: *Narcotics Safety and Awareness Act; November 2011*

\*\*NMS: *Narcotics Monitoring System; May 2012*